Myeloid Therapeutics Rebrands as Create Medicines, Expands Pipeline Beyond Myeloid Cells

Myeloid Therapeutics, a biotech company known for its focus on myeloid cell-based therapies, has announced a significant rebranding and expansion of its pipeline. The company, now known as Create Medicines, is broadening its scope to include multiple immune cell types and advancing several promising candidates in oncology and immunology.

Strategic Rebranding Reflects Expanded Focus

The decision to rebrand comes as the company's research and development efforts have outgrown its original myeloid-centric focus. Daniel Getts, Ph.D., CEO of Create Medicines, explained the rationale behind the name change: "Our clinical work in more than 40 patients has proven that we can tolerably and repeatedly program immune cells inside the body. We are now extending those capabilities to program multiple immune lineages for deeper, more durable responses."

This strategic shift is evident in the company's pipeline, which now includes therapies targeting T cells and NK cells in addition to myeloid cells. The rebranding reflects Create Medicines' commitment to in vivo multi-immune programming, a approach that could potentially offer more comprehensive and effective treatments for various diseases.

Advancing Clinical and Preclinical Programs

Create Medicines is making significant strides in its clinical programs. The company's lead candidates, MT-302 and MT-303, are currently in phase 1 trials. These in vivo mRNA CAR therapies are designed to reprogram immune cells to target TROP2 and GPC3, receptors overexpressed in certain cancers.

In addition to these ongoing trials, Create Medicines has ambitious plans for its pipeline:

1. MT-304: A HER2 multi-immune CAR therapy for breast cancer, engaging both NK and myeloid cells, is slated to enter clinical trials this year.
2. RNA Retrotransposon-based CAR-T: The company is developing what it claims to be the first-ever RNA retrotransposon-based in vivo CAR-T for B-cell depletion in oncology and autoimmunity.
3. Preclinical Pipeline: Create Medicines is advancing multiple preclinical programs spanning oncology and immunology, leveraging its multi-lineage approach.

Financial Backing and Future Outlook

Despite a reported restructuring earlier this year that narrowed the company's focus on its clinical candidates, Create Medicines appears to have strong financial support. The company raised $73 million in 2023 from a syndicate of investors including Hatteras Investment Partners, Arch Venture Partners, Newpath Partners, and 8VC.

CEO Getts emphasized the continued commitment of these investors to the company's success, suggesting that Create Medicines is well-positioned to pursue its expanded research and development strategy.

As Create Medicines moves forward with its rebranded identity and broadened focus, the biotech industry will be watching closely to see how its innovative approach to multi-immune programming translates into clinical outcomes and potential new treatments for patients.